Adenocarcinoma of the Stomach Clinical Trial
Official title:
A Phase II Study of Tesetaxel Administered at a Flat Dose Once Every 21 Days as Second-line Therapy to Subjects With Advanced Gastric Cancer
Tesetaxel is an orally administered chemotherapy agent of the taxane class. This study is being undertaken to evaluate the efficacy and safety of tesetaxel administered as second-line therapy to patients with advanced gastric cancer.
n/a
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00982592 -
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
|
Phase 2 | |
| Recruiting |
NCT04077255 -
EGFR-targeted Therapy for Gastric Cancer
|
Phase 2 | |
| Terminated |
NCT01233505 -
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT00098527 -
FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03647969 -
Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
| Terminated |
NCT00871273 -
Pharmacokinetic Study of Capecitabine After Total Gastrectomy for Stomach Adenocarcinoma
|
Phase 4 | |
| Recruiting |
NCT05729646 -
Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
|
Phase 2 | |
| Recruiting |
NCT06299163 -
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05315830 -
A Study of HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma Esophagogastric
|
Phase 1 | |
| Completed |
NCT00062374 -
Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction
|
Phase 2 | |
| Not yet recruiting |
NCT05970627 -
Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT02202759 -
A Study of MLN0264 in Patients With Cancer of the Stomach or Gastroesophageal Junction
|
Phase 2 | |
| Recruiting |
NCT01962519 -
Early Oral Feeding After Total Gastrectomy for Cancer
|
N/A | |
| Completed |
NCT00607594 -
Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer
|
Phase 2 | |
| Recruiting |
NCT06121700 -
Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer
|
Phase 2 | |
| Terminated |
NCT03722108 -
Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05715931 -
Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
|
Phase 2 | |
| Recruiting |
NCT02678182 -
Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial
|
Phase 2 | |
| Completed |
NCT01640782 -
Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach
|
Phase 3 | |
| Recruiting |
NCT05872685 -
Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)
|
Phase 2 |